Replies to post #85562 on Biotech Values

[drbio45]

I own a little achn, may buy more soon.

[turtlepower]

ARYX - Shot up towards the EOD on higher than normal volume. I find it a bit strange that they will discuss licensing efforts on 11/4 when they also stated the following on thursday

"With that said, as we move closer to completing the partnering process and negotiating a final agreement, we will be providing fewer details about where we stand in order to achieve the best possible result with those companies competing for the compound.”"

Nevertheless assuming they ensure a deal similar to what CRME got what are your expectations for a marketcap? CRME is probably the best comparison but since CRME has an IV I'm not sure whether value is attributed to that or not. CRME is currently about 250 million but if the weakness in the biotech sector abates may approach 300M. ARYX may at least reach half of that. I'm assuming Tercarfarin is not going to be given too much value if at all. 7505 is probably a wild card.